Pediatric Rheumatology Association of Japan recommendation for vaccination in pediatric rheumatic diseases

References

• Wallace DJ, Hahn BH. Dubois’ Lupus Erythematosus. 7th Ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins, 2007.
   Google Scholar
• Millet A, Decaux O, Perlat A, Grosbois B, Jego P. Systemic lupus erythematosus and vaccination. Eur J Intern Med. 2009; 20(3):236–41.
   PubMed Web of Science ®Google Scholar
• Goldblatt F, Chambers S, Rahman A, Isenberg DA. Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality. Lupus. 2009;18(8):682–89.
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol. 1995;22(7):1259–64.
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. European Working Party on Systemic Lupus Erythematosus: Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5): 299–308.
   PubMed Web of Science ®Google Scholar
• Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–93.
   PubMed Web of Science ®Google Scholar
• Baum J. Infection in rheumatoid arthritis. Arthritis Rheum. 1971;14(1):135–7.
   PubMedGoogle Scholar
• Gilliam BE, Wolff AE, Moore TL. Partial C4 deficiency in juvenile idiopathic arthritis patients. J ClinRheumatol. 2007;13(5):256–60.
   Web of Science ®Google Scholar
• Colmegna I, Alberts-Grill N. Parvovirus B19: its role in chronic arthritis. Rheum Dis Clin North Am. 2009;35(1):95–110.
   PubMed Web of Science ®Google Scholar
• Lossius A, Johansen JN, Torkildsen Ø, Vartdal F, Holmøy T. Epstein-Barr virus in systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis—association and causation. Viruses 2012;4(12):3701–30.
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Calabrese LH. Management of rheumatic disease with comorbid HBV or HCV infection. Nat Rev Rheumatol. 2012;8(6):348–57.
   PubMed Web of Science ®Google Scholar
• Pérez-Alvarez R, Dias-Lagares C, Garcia-Hernández F, Lopez-Roses L, Brito-Zerón P, Pérez-de-Lis M. et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Medicine (Baltimore). 2011;90(6):359–71. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Kinder AJ, Hassell AB, Brand J, Brownfield A, Grove M, Shadforth MF. The treatment of inflammatory arthritis with methotrexate in clinical practice: treatment duration and incidence of adverse drug reactions. Rheumatology (Oxford). 2005;44(1):61–6. (LoE; IVa)
   PubMed Web of Science ®Google Scholar
• Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301(7):737–44. (LoE; IVa)
   PubMed Web of Science ®Google Scholar
• Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol. 2004;31:2517–8. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmune Rev. 2011, doi:10.1016/j.autrev.2011.10.015 (LoE; IVb)
   Web of Science ®Google Scholar
• Atzeni F, Bendtzen K, Bobbio-Pallavicini F, Conti F, Cutolo M, Montecucco C, et al. Infections and treatment of patients with rheumatic diseases. ClinExpRheumatol. 2008;26(1 Suppl 48): S67–73. (LoE; VI)
   Web of Science ®Google Scholar
• Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52(7):1986–92. (LoE; IVa)
   PubMedGoogle Scholar
• Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum. 2009;61(3):300–4. (LoE; IVa)
   PubMedGoogle Scholar
• Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis. 2006;43(6):717–22. (LoE; IVa)
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 2003;48(8):2122–7. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Kim HA, Yoo CD, Baek HJ, Lee EB, Ahn C, Han JS, et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. ClinExpRheumatol. 1998;16(1):9–13. (LoE; V)
   Web of Science ®Google Scholar
• Sayarlioglu M, Inanc M, Kamali S, Cefle A, Karaman O, Gul A, et al. Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization. Lupus. 2004;13(4):274–8. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol. 2007;34(4):706–11. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Tam LS, Leung CC, Ying SK, Lee GK, Yim CW, Leung YY, et al. Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong . The role of TNF blockers in an area of high tuberculosis burden. ClinExpRheumatol. 2010; 28(5):679–85. (LoE; V)
   Web of Science ®Google Scholar
• Tam LS, Li EK, Wong SM, Szeto CC. Risk factors and clinical features for tuberculosis among patients with systemic lupus erythematosus in Hong Kong. Scand J Rheumatol. 2002;31(5):296–300. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Ray P, Black S, Shinefield H, Dillon A, Schwalbe J, Holmes S, et al. Risk of chronic arthropathy among women after rubella vaccination. JAMA. 1997;278(7):551–6. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Preblud SR. Some current issues relating to rubella vaccine. JAMA. 1985;254(2):253–6.(LoE; III)
   PubMed Web of Science ®Google Scholar
• Tingle AJ, Allen M, Petty RE, Kettyls GD, Chantler JK. Rubella-associated arthritis. I. Comparative study of joint manifestations associated with natural rubella infection and RA27/3 rubella immunization. Ann Rheum Dis. 1986;45(2):110–4. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Tingle AJ, Mitchell LA, Grace M, Middleton P, Mathias R, MacWilliam L, Chalmers A. Randomised double-blind placebo-controlled study on adverse effects of rubella immunization in seronegative women. Lancet. 1997;349(9061):1277–81.(LoE; II)
   PubMed Web of Science ®Google Scholar
• Peltola H, Heinonen O. Frequency of true adverse reactions to measles-mumps-rubella vaccine: A double-blind placebo-controlled trial in twins. Lancet. 1986;327:939–42. (LoE; II)
   Google Scholar
• Benjamin CM, Chew GC, Silman AJ. Joint and limb symptoms in children after immunization with measles, mumpus, and rubella vaccine. BMJ. 1992;304(6834): 1075–8.(LoE; IVa)
   PubMedGoogle Scholar
• Heijstek MW, Ott de Bruin LM, Bijl M, Borrow R, van der Klis F, Koné-Paut I, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–12.
   PubMed Web of Science ®Google Scholar
• van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3): 414–22.
   PubMed Web of Science ®Google Scholar
• Kroger AT, Atkinson WL, Marcuse EK, Pickering LK;Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General Recommendations on ImmunizationRecommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2006;55(RR-15):1–48.
   PubMedGoogle Scholar
• Höyeraal HM, Mellbye OJ. Humoral immunity in juvenille rheumatoid arthritis. Ann Rheum Dis. 1974;33(3):248–54. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Denman EJ, Denman AM, Greenwood BM, Gall D, Heath RB. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann rheum Dis. 1970;29(3):220–31. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Kashef S, Ghazizadeh F, Derakhshan A, Farjadian S, Alyasin S. Antigen-specific antibody response in juvenile-onset SLE patients following routine immunization with tetanus toxoid. Iran J Immunol. 2008;5(3):181–4. (LoE; III)
   PubMedGoogle Scholar
• Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41(10):1828–34. (LoE; IVb)
   PubMedGoogle Scholar
• Miyamoto M, Ono E, Barbosa C, Terreri M, Hilário M, Salomão R, de Moraes-Pinto M. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus. 2011;20(7): 736–44. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Bingham CO III, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74. (LoE; III)
   PubMedGoogle Scholar
• Tay L, Leon F, Vratsanos G, Raymond R, Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. ArthritisResTher. 2007;9(2):R38. Doi:10.1186/ar2174 (LoE; III)
   PubMed Web of Science ®Google Scholar
• Jarret MP, Schiffman G, Barland P, Grayzel AI. Impaired response to pneumococcal vaccine in systemic lupus erythematosus. Arthritis Rheum. 1980;23(11):1287–93. (LoE; III)
   PubMedGoogle Scholar
• Croft SM, Schiffman G, Snyder E, Herrmann K, James K, Jarrett MP. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. J Rheumatol. 1984;11(2):141–6. (LoE; III)
   Web of Science ®Google Scholar
• Lipnick RN, Karsh J, Stahl NI, Blackwelder WC, Schiffman G, Klippel JH. Pneumococcal immunization in patients with systemic lupus erythematosus treated with immunosuppressives. J Rheumatol. 1985;12(6):1118–21. (LoE; III)
   PubMed Web of Science ®Google Scholar
• O'dell Jr, Gilg J, Palmer W, Haire C, Klassen L, Moore G. Pneumococcal vaccine in rheumatoid arthritis. J ClinRheumatol. 1996;2(2):59–63. (LoE; III)
   Google Scholar
• Mease PJ, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. J Rheumatol. 2004;31(7):1356–61. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):106–11. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol. 2007;34(5):952–7. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Gelinck LBS, van der Bijl AE, Visser LG, Huizinga TW, van Hogezand RA, Rijkers GT, Kroon FP. Synergistic immunosuppressive effect of anti-TNF combined with methotrexate on antibody responses to 23 valent pneumococcal polysaccharide vaccine. Vaccine. 2008;26(27–28):3528–33. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Melmed GY, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148–54. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Roseman C, Jonsson G, et al. Antibody response is reduced followingvaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitor. Arthritis Rheum. 2011;63(12):3727–32. (LoE; III)
   Google Scholar
• Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? J Rheumatol. 2006;33(8):1469–71. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34(2):272–9. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2004;33(4):283–8. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, Trachana M, Pratsidou-Gertsi P, Tritsoni M, Theodoridou M. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28(31):5109–13. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Håwi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010;12(3):R111. doi: 10.1186/ar3047(LoE; III)
   PubMed Web of Science ®Google Scholar
• Stojanovich L. Influenza vaccination of patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). ClinDevImmunol. 2006;13(2–4):373–5. (LoE; III)
   Google Scholar
• Brodman R, Gilfillan R, Glass D, Schur PH. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):735–40. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Louie J S, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, et al. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):790–2. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Pons V G, Reinertsen JL, Steinberg AD, Dolin R. Decreased cell-mediated cytotoxicity against virus-infected cells in systemic lupus erythematosus. J Med Virol. 1979;4(1):15–23. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, Hahn B. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 1979;242(1):53–6. (LoE; III)
   Google Scholar
• Chalmers A, Scheifele D, Patterson C, Williams D, Weber J, Shuckett R, Teufel A. Immunization of patients with rheumatoid arthritis against influenza: a study of vaccine safety and immunogenicity. J Rheumatol. 1994;21(7):1203–6. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Mercado U, Acosta H, Avendaño L. Influenza vaccination of patients with systemic lupus erythematosus. Rev Invest Clin. 2004;56(1): 16–20. (LoE; III)
   PubMedGoogle Scholar
• Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis. 2006;65(2):191–4. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Del Porto F, Laganà B, Biselli R, Donatelli I, Campitelli L, Nisini R, et al. Influenza vaccine administration in patients with systemic lupus erythematosus and rheumatoid arthritis. Safety and immunogenicity. Vaccine. 2006;24(16):3217–23. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Zycinska K, Romanowska M, Nowak I, Rybicka K, Wardyn KA, Brydak LB. Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J PhysiolPharmacol. 2007;58(Suppl 5):819–28. (LoE; III)
   Google Scholar
• Denman EJ, Denman AM, Greenwood BM, Gall D, Heath RB. Failure of cytotoxic drugs to suppress immune responses of patients with rheumatoid arthritis. Ann Rheum Dis. 1970;29(3):220–31. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus erythematosus. A double-blind trial. Ann Intern Med. 1978;88(6):729–34. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Ristow SC, Douglas RG Jr, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Ann Intern Med. 1978;88(6):786–9. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Abu-Shakra M, Press J, Varsano N, Levy V, Mendelson E, Sukenik S, Buskila D. Specific antibody response after influenza immunization in systemic lupus erythematosus. J Rheumatol. 2002;29(12):2555–7. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Holvast A, Huckriede A, Wilschut J, Horst G, De Vries JJ, Benne CA. et al. Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.Ann Rheum Dis. 2006;65(7):913–8. (LoE; III)
   PubMedGoogle Scholar
• Holvast A, van Assen S, de Haan A, Huckriede A, Benne CA, Westra J, et al. Studies of cell-mediated immune responses to influenza vaccination in systemic lupus erythematosus. Arthritis Rheum. 2009;60(8):2438–47. (LoE; III)
   PubMedGoogle Scholar
• Wiesik-Szewczyk E, Romanowska M, Mielnik P, Chwalińska-Sadowska H, Brydak LB, Olesińska M, Zabek J. Anti-influenza vaccination in systemic lupus erythematosus patients: an analysis of specific humoral response and vaccination safety. Clin Rheumatol. 2010;29(6):605–13. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Setti M, Fenoglio D, Ansaldi F, Filaci G, Bacilieri S, Sticchi L, et al. Influenza vaccination with a virosomal vaccine does not affect clinical course and immunological parameters in scleroderma patients. Vaccine 2009;27(25–26):3367–72. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Litinsky I, Balbir A, Zisman D, Mandelboim M, Mendelson E, Feld J, et al. Vaccination against influenza in patients with systemic sclerosis. Clin Exp Rheumatol. 2012;30(Suppl 71):S7–11. (LoE; III)
   PubMedGoogle Scholar
• Malleson PN, Tekano JL, Scheifele DW, Weber JM. Influenza immunization in children with chronic arthritis: a prospective study. J Rheumatol. 1993;20(10):1769–73. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Kanakoudi-Tsakalidou F, Trachana M, Pratsidou-Gertsi P, Tsitsami E, Kyriazopoulou-Dalaina V. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol. 2001;19(5):589–94. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Ogimi C, Tanaka R, Saitoh A, Oh-Ishi T. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 2011;30(3):208–11. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 851–6.(LoE; III)
   PubMed Web of Science ®Google Scholar
• Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104(2):444–53. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Kubota T, Nii T, Nanki T, Kohsaka H, Harigai M, Komano Y, et al. Anti-tumor necrosis factor therapy does not diminish the immune response to influenza vaccine in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2007;17(6):531–3. (LoE; III)
   PubMedGoogle Scholar
• Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008;67(5):713–6. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Elkayam O, Bashkin A, Mandelboim M, Litinsky I, Comaheshter D, Levartovsky D, et al. The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. Semin Arthritis Rheum. 2010;39(6):442–7. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–41. (LoE; III)
   PubMed Web of Science ®Google Scholar
• van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81. (LoE; III)
   PubMedGoogle Scholar
• Arad U, Tzadok S, Amir S, Mandelboim M, Mendelson E, Wigler I, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643–8. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Dell’Era L, Corona F, Daleno C, Scala A, Principi N, Esposito S. Immunogenicity, safety and tolerability of MF59-adjuvanted seasonal influenza vaccine in children with juvenile idiopathic arthritis. Vaccine. 2012;30(5):936–40. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Shinoki T, Kikuchi M, Kaneko U, et al. Safety and response to influenza vaccine in patients with juvenile rheumatoid arthritis receiving tocilizumab. Mod Rheumatol 2012; DOI 10.1007/s10165–012–0595–z (LoE; III)
   PubMedGoogle Scholar
• Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D. Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol. 2000;27(7):1681–5. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Aikawa NE, Goldenstein-Schainberg C, Vendramini M, Campos LMA, Saad CG, Moraes JB, et al. Autoimmune response following influenza H1N1 vaccination in patients with juvenile idiopathic arthritis. Pediatric Rheumatology. 2011;9(Suppl 1):P. 133. (LoE; III)
   Google Scholar
• Elkayam O, Amir S, Mendelson E, Schwaber M, Grotto I, Wollman J, et al. Efficacy and safety of vaccination against pandemic 2009 influenza A (H1N1) virus among patients with rheumatic diseases. Arthritis Care Res (Hoboken). 2011;63(7):1062–7. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Shimizu M, Ueno K, Yachie A. Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab. Clin Vaccine Immunol. 2012;19(10):1700–2.(LoE; V)
   PubMedGoogle Scholar
• Maillefert JF, Sibillia J, Toussirot E, Vignon E, Eschard JP, Lorcerie B, et al. Rheumatic disorders developed after hepatitis B vaccination. Rheumatology. 1999;38(10):978–83. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. A case-control study of serious autoimmune adverse events following hepatitis B immunization. Autoimmunity. 2005;38(4):295–301. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Sturkenbbom MCFB, Rozenberg S, Begaud B, et al. Vaccination against hepatitis B and lupus erythematosus. Pharmacoepidemiol Drug Safety 2000;9:S71.(LoE; IVb)
   PubMedGoogle Scholar
• Elkayam O, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. Ann Rheum Dis. 2002;61(7):623–5. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Kasapçopur O, Cullu F, Kamburoğlu-Goksel A, Cam H, Akdenizli E, Calýkan S, et al. Hepatitis B vaccination in children with juvenile idiopathic arthritis. Ann Rheum Dis. 2004;63(9):1128–30. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Beran J, Dedek P, Stepánová V, Spliio M, Pozler O. Safety and immunogenicity of a combined vaccine against hepatitis A and B in patients with autoimmune hepatitis. Cent Eur J Public Health. 2005;13(1):20–3. (LoE; IVb)
   PubMedGoogle Scholar
• Erkek E, Ayaslioglu E, Erkek AB, Kurtipek GS, Bagci Y. Response to vaccination against hepatitis B in patients with Behcet's disease. J Gastroenterol Hepatol. 2005;20(10):1508–11. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Kuruma KA, Borba EF, Lopes MH, de Carvalho JF, Bonfá E. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus. 2007;16(5):350–4. (LoE; IVb)
   PubMed Web of Science ®Google Scholar
• Aytac MB, Kasapcopur O, Aslan M, Erener-Ercan T, Cullu-Cokugras F, Arisoy N. Hepatitis B vaccination in juvenile systemic lupus erythematosus. ClinExpRheumatol. 2011;29(5):882–6. (LoE; III)
   Web of Science ®Google Scholar
• Erguven M, Kaya B, Hamzah OY, Tufan F. Evaluation of immune response to hepatitis A vaccination and vaccine safety in juvenile idiopathic arthritis. J Chin Med Assoc. 2011;74(5):205–8. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Tam L-S, Chan AYK, Chang PKS, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus; Association with human papillomavirus infection. Arthritis Rheum. 2004;50(11):3619–25. (LoE; IVb)
   PubMedGoogle Scholar
• Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, Cason J. High risk of human papillomavirus type 16 infection and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Care Res. 2007;57(4): 619–25. (LoE; III)
   Web of Science ®Google Scholar
• Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72:659–64(LoE; III).
   PubMed Web of Science ®Google Scholar
• Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21(2): 158–61. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Scherpenisse M, Groot N, Tacke C, Schepp RM, Buisman AM. et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study.Ann Rheum Dis. 2014;73(8):1500–7. (LoE; III)
   PubMedGoogle Scholar
• Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, et al. Human papillomavirus vaccine and systemic lupus erythematosus. ClinRheumatol. 2013;32(9):1301–7. doi 10.1007/s10067–013–2266–7. (LoE; V)
   Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med. 2014;275(4):398–408 (LoE; III)
   PubMed Web of Science ®Google Scholar
• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safetysurveillance for quadrivalent human papillomavirusrecombinant vaccine. JAMA. 2009;302(7):750–7. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Tomilijenovic L, Shaw CA. Death after quadrivalent human papillomavirus vaccination: causal or coincidental? PharmaceutReg Affairs 2012;S12:001. Doi: 10.4172/2167–7689.S12–001. (LoE;V)
   Google Scholar
• Miyamoto M, Ono E, Barbosa C, Terreri M, Hilário M, Salomão R, de Moraes-Pinto M. Vaccine antibodies and T- and B-cell interaction in juvenile systemic lupus erythematosus. Lupus. 2011;20(7):736–44. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Borte S, Liebert UG, Borte M, Sack U. Efficacy of measles, mumps and rubella revaccination in children with juvenile idiopathic arthritis treated with methotrexate and etanercept. Rheumatology (Oxford). 2009;48:144–8. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Korematsu S, Miyahara H, Kawano T, Yamada H, Akiyoshi K, Sato K, et al. A relapse of systemic type juvenile idiopathic arthritis after a rubella vaccination in a patient during a long-term remission period. Vaccine. 2009;27(37):5041–2. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Heijstek M W, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(10):1384–7. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Kamphuis S, Armbrust W, Swart J, Gorter S, de Vries LD, et al. Effects of the live attenuated measles-mumps-rubella booster vaccination on disease activity in patients with juvenile idiopathic arthritis in arandomized trial. JAMA. 2013;309(23):2449–56. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Marin M, Guris D, Chaves SS, Schmid S, Seward JF;Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention(CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4):1–40. (LoE; VI)
   PubMedGoogle Scholar
• Rahier JF, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49(10): 1815–27. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Kroger AF, Sumaya CV, Pickering LK, Atkinson WL. General recommendation on immunization; Recommendations of the Advisory Committee on Immunization Practice (ACIP). MMWR 2011;60:3–61.(LoE; V)
   Google Scholar
• Pileggi GM, de Souza CBS, Ferriani VPL. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. Arthritis Care Res. 2010;62(7):1034–1039. (LoE; V)
   Google Scholar
• Abe T, Homma M. Immunological reactivity in patients with systemic lupus erythematosus. Humoral antibody and cellular immune responses.Acta Rheumatol Scand. 1971;17(1):35–46. (LoE; V)
   PubMedGoogle Scholar
• Kiray E, Kasapcopur O, Bas V, Kamburoglu-Goksel A, Midilli K, Arisoy N, Tastan Y. Purified protein derivative response in juvenile idiopathic arthritis. J Rheumatol. 2009;36(9):2029–32. (LoE; III)
   PubMed Web of Science ®Google Scholar
• Rodrigues LC, Diwan VK, Wheeler JG. Protective effect of BCG against tuberculosis meningitis and military tuberculosis:A meta-analysis. Int J Epidemiol. 1993;22(6):1154–8. (LoE; I)
   PubMed Web of Science ®Google Scholar
• Takamatsu I. Kameda M, Inoue T, Toyoshima K. Assessment of effectiveness of BCG vaccination against childhood tuberculosis. Kekkaku. 1995;70(9):561–6 (Japanese). (LoE; V)
   Google Scholar
• Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin SL, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum. 2008;58(5):1496–504. (LoE; V)
   PubMedGoogle Scholar
• Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Pérez N, Silva CA, et al. Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum. 2010;62(6):1792–802. (LoE; V)
   PubMedGoogle Scholar
• Weinstein M. Inflammation at a previous inoculation site: an unusual presentation of Kawasaki disease. Can Med Assoc J. 2006;174(4):459–60. (LoE V)
   Web of Science ®Google Scholar
• Antony D, Jessy PL. Involvement of BCG scar in Kawasaki disease. Indian Pediatr. 2005;42(1):83–4. (LoE; V)
   PubMed Web of Science ®Google Scholar
• Fujikawa S, Okuni M. A nationwide surveillance study of rheumatic diseases among Japanese children. Acta Paediatr Jpn. 1997;39(2):242–4.
   PubMedGoogle Scholar
• Cheent K, Nolan J, Shariq S, Kiho L, Pal A, Arnold J. Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4(5):603–5.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2013;11(3):286–92.
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Church JA, Silverman N, Barry M, Targan SR, Dubinsky MC. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4(10):1255–8.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Cucchiara S, Hyams JS, Steinwurz F, Nuti F, Travis SP, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol. 2011;106(2): 214–23.
   PubMed Web of Science ®Google Scholar